Related references
Note: Only part of the references are listed.Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma
Thomas A. Ollila et al.
BLOOD (2021)
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
George W. Wright et al.
CANCER CELL (2020)
Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy
Manuel Montesinos-Rongen et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL
Magdalena Klanova et al.
BLOOD (2019)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targetable genetic features of primary testicular and primary central nervous system lymphomas
Bjoern Chapuy et al.
BLOOD (2016)
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP
Norbert Schmitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era
Andres J. M. Ferreri et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2011)
Share Paper
